Rabbit anti-Human TET2 Polyclonal Antibody | anti-TET2 antibody

TET2, NT (TET2, KIAA1546, Methylcytosine dioxygenase TET2) (FITC)

Cat. Num. AAA6354879

• Gene Names: TET2; MDS; KIAA1546
• Reactivity: Human
• Applications: Western Blot
• Purity: Purified by Protein A Affinity Chromatography.
• Synonyms: TET2; Polyclonal Antibody; NT (TET2; KIAA1546; Methylcytosine dioxygenase TET2) (FITC); Methylcytosine dioxygenase TET2; anti-TET2 antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Isotype: IgG
• Purity/Purification: Purified by Protein A Affinity Chromatography.
• Form/Format: Supplied as a liquid in PBS, pH 7.2. No preservative added. Labeled with Fluorescein Isothiocyanate (FITC).

• Applicable Applications for anti-TET2 antibody: Western Blot (WB), FLISA
• Application Notes: WB: 1:100-500; FLISA: 1:1,000; Applications are based on unconjugated antibody.
• Immunogen: TET2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 527-554 amino acids from the N-terminal region of human TET2.
• Conjugate: FITC
• Note: Preservative Free
• Special Handling: Light sensitive
• Preparation and Storage: Store product at 4 degree C if to be used immediately within two weeks. For long-term storage, aliquot to avoid repeated freezing and thawing and store at -20 degree C. Aliquots are stable at -20 degree C for 12 months after receipt. Dilute required amount only prior to immediate use. Further dilutions can be made in assay buffer. Caution: FITC conjugates are sensitive to light. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Western Blot (WB)

(TET2 Antibody (N-term) western blot analysis in A549 cell line lysates (35ug/lane).This demonstrates the TET2 antibody detected the TET2 protein (arrow).)

Related Product Information for anti-TET2 antibody

TET2 may catalyze the conversion of methylcytosine (5mC) to 5-hydroxymethylcytosine (hmC) (By similarity). Play an important role in the regulation of myelopoiesis.

Product Categories/Family for anti-TET2 antibody

Antibodies; Enzymes; Oxidase

References

Mallo, M., et al. Haematologica 95(10):1798-1800(2010). Smith, A.E., et al. Blood (2010). In press: Tefferi, A., et al. Leukemia 24(7):1302-1309(2010). Kim, S.T., et al. Prostate (2010). In press: Rocquain, J., et al. BMC Cancer 10, 401 (2010).

NCBI and Uniprot Product Information

• NCBI GI #: 187761317
• NCBI GeneID: 54790
• NCBI Accession #: NP_001120680.1; NP_060098.3
• NCBI GenBank Nucleotide #: NM_001127208.2
• UniProt Accession #: Q6N021; Q2TB88; Q3LIB8; Q96JX5; Q9HCM6; Q9NXW0; B5MDU0
• Molecular Weight: 133,481 Da
• NCBI Official Full Name: methylcytosine dioxygenase TET2 isoform a
• NCBI Official Synonym Full Names: tet methylcytosine dioxygenase 2
• NCBI Official Symbol: TET2
• NCBI Official Synonym Symbols: MDS; KIAA1546
• NCBI Protein Information: methylcytosine dioxygenase TET2
• UniProt Protein Name: Methylcytosine dioxygenase TET2
• Protein Family: Tetraspanin
• UniProt Gene Name: TET2
• UniProt Synonym Gene Names: KIAA1546
• UniProt Entry Name: TET2_HUMAN

NCBI Description

The protein encoded by this gene is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. The encoded protein is involved in myelopoiesis, and defects in this gene have been associated with several myeloproliferative disorders. Two variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2011]

Uniprot Description

TET2: Catalyzes the conversion of methylcytosine (5mC) to 5- hydroxymethylcytosine (hmC). Plays an important role in myelopoiesis. The clear function of 5-hydroxymethylcytosine (hmC) is still unclear but it may influence chromatin structure and recruit specific factors or may constitute an intermediate component in cytosine demethylation. TET2 is frequently mutated in myeloproliferative disorders (MPD). These constitute a heterogeneous group of disorders, also known as myeloproliferative diseases or myeloproliferative neoplasms (MPN), characterized by cellular proliferation of one or more hematologic cell lines in the peripheral blood, distinct from acute leukemia. Included diseases are: essential thrombocythemia, polycythemia vera, primary myelofibrosis (chronic idiopathic myelofibrosis). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. Defects in TET2 are a cause of polycythemia vera (PV). A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly. TET2 is frequently mutated in systemic mastocytosis; also known as systemic mast cell disease. A condition with features in common with myeloproliferative diseases. It is a clonal disorder of the mast cell and its precursor cells. The clinical symptoms and signs of systemic mastocytosis are due to accumulation of clonally derived mast cells in different tissues, including bone marrow, skin, the gastrointestinal tract, the liver, and the spleen. Defects in TET2 are a cause of myelodysplastic syndrome (MDS). A heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS). Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. Myelodysplastic syndromes are considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. Belongs to the TET family. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: Tumor suppressor; EC 1.14.11.n2; Oxidoreductase

Chromosomal Location of Human Ortholog: 4q24

Molecular Function: protein binding; DNA binding; zinc ion binding; ferrous iron binding

Biological Process: spleen development; protein amino acid O-linked glycosylation; hemoglobin metabolic process; cell cycle; regulation of gene expression, epigenetic; post-embryonic development; myeloid progenitor cell differentiation; cytosine metabolic process; 5-methylcytosine catabolic process; gene expression; positive regulation of transcription from RNA polymerase II promoter; myeloid cell differentiation; kidney development

Disease: Myelodysplastic Syndrome